Skip to Main Content
Free Trials

Powering Innovation that Drives Human Advancement

Ansys at ISPE Biotech 2025

Ansys is exhibiting at ISPE Biotech 2025 from June 2-3, 2025, in Boston, MA. Explore cutting-edge in silico methodologies that accelerate clinical trials, optimize manufacturing processes, and enhance drug delivery device design. Connect with experts and engage in discussions to advance innovation in pharmaceutical development.

While you are there, visit our booth for exciting technical presentations and speak with our healthcare industry experts about how Ansys technology supports the design, development, and even the regulatory review of today’s innovative silico processes.

Date:
June 2 - June 3, 2025

Venue:
The Westin Boston Seaport District
425 Summer St
Boston, MA 02210

Digitally Transforming Drug Manufacturing and Drug Delivery

Developing traditional drug manufacturing and delivery processes requires considerable time and financial investment. In silico approaches are the only viable solution to accelerate innovation and dramatically reduce costs and time to market. Applying engineering simulation and mechanistic modeling to identify the best delivery route or to scale up production equipment from lab scale to mass production is crucial to achieving regulatory approval on a sustainable timescale and budget.

Resources

DNA and microscope

Using Digital Twin Technology for Pharma

Digital twin technology is used across industries to provide real-time insights into processes and systems. But in the biopharmaceutical industry, where successful scaling from discovery to commercial launch requires the meticulous integration of engineering and biology, the dynamic qualities of pharma digital twins make them especially valuable.

Learn More About Digital Twins
Ansys Connect Healthcare Webinar

Disruption in Healthcare Is Here: Are You Ready?

Engineering simulation, or the use of computer models to assess the behavior of a device or treatment in its working environment, is now used by 85% of the top 50 healthcare companies as part of their product and process development. Simulating the performance of drugs, devices and therapies in a low-risk, cost-effective virtual environment can develop (disruptive) innovations much faster and at lower cost. Healthcare pioneers have repeatedly reported returns on investment of greater than 500%. Ansys is fully embracing the in silico approach by creating the necessary software and enabling access to computational power to make simulation pervasive from startups to large global companies, from concept to in-patient performance.

Learn More About Simulation
Digital-Twin-healthcare-1.jpg

Engineering Simulation: A Promising Tool for Securing Regulatory Approvals

The United States Congress, the US Food & Drug Administration (FDA) and the European Parliament have all publicly recognized the value engineering simulation can add during the process of demonstrating product performance and gaining approvals. Today a number of healthcare companies and technology providers are joining forces within the Avicenna Alliance to accelerate the pace of adoption. With so many doors open, the failure to use engineering simulation as part of the regulatory approval process not only misses a major opportunity, but also wastes precious resources.

Get White Paper

Get in contact with Ansys

Email us